These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9159328

  • 1. p53 and HER-2/neu overexpression in ovarian borderline tumors.
    Eltabbakh GH, Belinson JL, Kennedy AW, Biscotti CV, Casey G, Tubbs RR.
    Gynecol Oncol; 1997 May; 65(2):218-24. PubMed ID: 9159328
    [Abstract] [Full Text] [Related]

  • 2. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B.
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [Abstract] [Full Text] [Related]

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP.
    Cancer; 1997 Apr 15; 79(8):1587-94. PubMed ID: 9118043
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct 15; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Expression of cell regulatory proteins in ovarian borderline tumors.
    van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF.
    Cancer; 1996 May 15; 77(10):2092-8. PubMed ID: 8640675
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R, Che M, Khalifeh I, Malone JM, Morris R, Lawrence WD, Munkarah AR.
    Cancer; 2003 Oct 01; 98(7):1423-9. PubMed ID: 14508829
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
    Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC.
    Gynecol Oncol; 1994 Feb 01; 52(2):232-6. PubMed ID: 7508877
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.